Trial Profile
Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2012
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 14 Apr 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 22 Mar 2012 New trial record